. Author manuscript; available in PMC: 2015 Jul 30.

Published in final edited form as: Haemophilia. 2013 Nov 22;20(2):230–237. doi: 10.1111/hae.12302

Table 2.

Inhibitor titer elevations detected at enrollment and during the study according to selected demographic and clinical characteristics.

	Detected at Enrollment	Detected During Study Follow-up	Total Detected
Non-Severe	3/9 (33%)	5/14 (36%)	8/23 (35%)
Age >5 years	4/9 (44%)	6/14 (43%)	10/23 (43%)
Exposure Days >150	3/9 (33%)	2/14 (14%)	5/23 (22%)
Exposure Days>20	8/9 (89%)	5/14 (36%)	13/23 (57%)
White Non-Hispanic Ethnicity	7/9 (78%)	10/14 (71%)	17/23 (74%)
High Risk Mutation	8/9 (89%)	10/14 (71%)	18/23 (78%)
Initial Titer >1.0 NBU	4/9 (44%)	11/14 (79%)	15/23 (65%)
Peak Titer >1.0 NBU	4/9 (44%)	11/14 (79%)	15/23 (65%)
Peak Titer >5.0 NBU	2/9 (22%)	5/14 (36%)	7/23 (30%)
No Clinical Indication	9/9 (100%)	5/14 (36%)	14/23 (61%)

NBU = Nijmegen Bethesda Units